Intratympanic Injection of Dexamethasone
Authors:
- Christopher A. HargunaniCHChristopher A. Hargunani
- J. Beth KemptonJKJ. Beth Kempton
- Jacqueline M. DeGagneJDJacqueline M. DeGagne
- Dennis R. TruneDTDennis R. Trune
- 1 June 2006
- journal article
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 27 (4) , 564-569
Abstract
Intratympanically injected dexamethasone 21-phosphate is converted to its active form dexamethasone in the inner ear and follows the distribution of the glucocorticoid receptor. Although dexamethasone is routinely delivered intratympanically for hearing loss, we know little of its inner ear pharmacokinetics. Dexamethasone 21-phosphate is the pharmaceutical compound available for injection, but it must be converted to its biologically active form (dexamethasone) to bind to the glucocorticoid receptor. Therefore, the current study was conducted to determine the time course of dexamethasone 21-phosphate movement from the middle ear into the inner ear, its conversion to dexamethasone, and the distribution of both forms relative to the glucocorticoid receptor. BALB/c mice were injected intratympanically with the prodrug dexamethasone 21-phosphate and inner ears collected at postinjection times ranging from 5 minutes to 7 days. Ears were immunohistochemically stained for dexamethasone 21-phosphate, dexamethasone, and the glucocorticoid receptor. Both forms of dexamethasone were seen in the inner ear within 15 minutes, reaching their highest staining intensity at 1 hour. Neither drug was seen after 24 hours. The strongest staining occurred in the spiral ligament, organ of Corti, spiral ganglion, and vestibular sensory epithelia. Distribution of the drug paralleled locations of the glucocorticoid receptor except in the stria vascularis marginal cells, which stained heavily for the receptor but not the drug. Dexamethasone rapidly travels from the middle ear into the inner ear and converts to its active form. The drug distribution follows that of the glucocorticoid receptor. However, it probably has little impact on ear tissues after 24 hours.Keywords
This publication has 32 references indexed in Scilit:
- Intratympanic Steroid Perfusion for Refractory Sudden Sensorineural Hearing LossOtolaryngology–Head and Neck Surgery, 2005
- Determination of prednisolone in the cochlear tissueHearing Research, 2002
- Intratympanic Steroid Injections for Intractable Ménière's DiseaseThe Laryngoscope, 2001
- Sudden Sensorineural Hearing LossJAMA Otolaryngology–Head & Neck Surgery, 2001
- Chronic Intrathecal Administration of Dexamethasone Sodium Phosphate: Pharmacokinetics and Neurotoxicity in an Animal ModelNeurosurgery, 2000
- Corticosteroid Pharmacokinetics in the Inner Ear Fluids: An Animal Study Followed by Clinical ApplicationThe Laryngoscope, 1999
- Hearing results of intratympanic steroid treatment of endolymphatic hydropsThe Laryngoscope, 1998
- Methotrexate management of immunemediated cochleovestibular disordersOtolaryngology–Head and Neck Surgery, 1997
- Tissue specific levels of glucocorticoid receptor within the rat inner earHearing Research, 1993
- XCIII Vasomotor Labyrinthine IschemiaAnnals of Otology, Rhinology & Laryngology, 1950